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Zusammenfassung
Mit der Einführung der cisplatinhaltigen Chemotherapie und der
Optimierung der chirurgischen Behandlung hat sich die Prognose
der malignen Keimzelltumoren (KZT) bei Kindern dramatisch ver-
bessert. Die cisplatinhaltige Chemotherapie resultiert in der Regel in
einer guten systemischen Tumorkontrolle. Jedoch können lokale
Rezidive auftreten, wenn keine ausreichende lokale Behandlung er-
reicht wird. Daher müssen die Parameter Alter, primäre Tumorloka-
lisation und Histologie in den therapeutischen Überlegungen be-
rücksichtigt werden. Bei den meisten gonadalen KZT kann eine
komplette Tumorresektion erreicht werden, da diese oft eine Tu-
morkapsel haben und besonders Hodentumoren zumeist früh er-
kannt werden. Dagegen ist eine komplette primäre Resektion bei
vielen extragonadalen KZT z.B. der Steißbeinregion oder des Media-
stinums nicht möglich. Hier erleichtert eine präoperative oder neo-
adjuvante Chemotherapie nach klinischer Diagnosestellung anhand
der radiologischen Befunde und der Tumormarker-Konstellation die
komplette Tumorentfernung während der verzögerten Tumorresek-
tion. In besonderen Fällen kann der Effekt der Chemotherapie auf
die lokale Tumorkontrolle durch eine lokoregionale Tiefenhyper-
thermie-Behandlung potenziert werden. Bei intrakranialer Lokalisa-
tion ist die komplette Resektion oft unmöglich und teilweise mit
schwerwiegenden Komplikationen behaftet. Daher ist bei nichtse-
zernierenden KZT eine Tumorbiopsie notwendig. Die Radiotherapie,
deren Dosis entsprechend der Histologie stratifiziert wird, kann sig-
nifikant zur lokalen Tumorkontrolle der intrakranialen KZT beitra-
gen, so dass in ausgewählten Fällen keine Resektion erforderlich
ist. Diese allgemeinen Erwägungen werden in nationalen und inter-
nationalen kooperativen Therapiestudien berücksichtigt. In den
meisten aktuellen Protokollen wird die Therapie risikostratifiziert an-
hand der Parameter Alter, Lokalisation, Histologie, Stadium, Resek-
tionsstatus und der Tumormarker Alpha1-Fetoprotein (AFP) und hu-
manes Choriogonadotropin (β-HCG). Innerhalb dieser Studien wer-
den für die Gesamtgruppe Heilungsraten über 80% erreicht. Darü-
ber hinaus konnte die Prognose der früheren Hochrisiko-Gruppen
deutlich gebessert werden, während eine zunehmende Zahl von
Niedrigrisiko-Patienten nach der Operation ausschließlich nachbe-
obachtet oder mit deutlich reduzierter Chemotherapie behandelt
wird. Da aktuelle molekularbiologische Studien differenzierte gene-
tische Muster bei KZT im Kindes- und Jugendalter aufzeigen, die
sich von denen bei KZT im Erwachsenenalter unterscheiden, ist zu
erwarten, dass zukünftige kombinierte klinische und genetische
Studien für die Risikobeurteilung bei KZT bei Kindern hilfreich sein
werden.
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Summary
The introduction of cisplatinum chemotherapy and current ad-
vances in the surgical treatment have resulted in a dramatic im-
provement of the prognosis of children with malignant germ cell tu-
mors (GCT). Cisplatinum chemotherapy generally results in suffi-
cient systemic tumor control, but local relapses may still occur in
patients who did not receive adequate local treatment. Therefore,
the therapeutic consideration must take into account age, primary
site of the tumor, and its histology. In gonadal tumors, there is a
high chance of primary complete resection since these tumors tend
to be encapsulated, and particularly testicular GCT are often detect-
ed at a low tumor stage. In contrast, a primary complete resection
may be impossible in large nongonadal tumors such as sacrococ-
cygeal or mediastinal GCT. In these tumors, a neoadjuvant or pre-
operative chemotherapy after clinical diagnosis by imaging and
evaluation of tumor markers significantly facilitates complete resec-
tion on delayed surgery. In addition, the impact of chemotherapy on
local tumor control may be enhanced by locoregional hyperther-
mia. In most intracranial GCT complete resection is impossible and
may be associated with significant morbidity. Nevertheless, biopsy
is essential for diagnosis in nonsecreting tumors. In intracranial
GCT, radiotherapy significantly contributes to local tumor control,
and doses are stratified according to histology. These general con-
siderations have been integrated into national and international co-
operative treatment protocols. In most current protocols, treatment
is stratified according to an initial risk assessment that includes the
parameters age, site, histology, stage, completeness of resection
and the tumor markers alpha1-fetoprotein (AFP) and human chori-
ogonadotropin (β-HCG). With such modern protocols overall cure
rates above 80% can be achieved. Moreover, the previously high-
risk groups may now expect a favorable prognosis with this risk-
adapted treatment, whereas an increasing number of low-risk pa-
tients are treated expectantly or with significantly reduced
chemotherapy. As current biologic studies reveal distinct genetic
patterns in childhood GCT, it can be expected that further combined
clinical and genetic studies will be valuable for risk assessment of
childhood GCT. 
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Introduction
The past two decades have been characterized by a dramatic
improvement of the prognosis of malignant germ cell tumors
(GCT) both in the adult and in the pediatric population. This
can mainly be attributed to national and international cooper-
ative therapeutic protocols that utilized cisplatinum-based
combination chemotherapy integrated into a multimodal ther-
apeutic approach. Although the first pediatric trials have been
designed in the light of the previous experience in malignant
testicular GCT in adults, these studies have soon revealed the
particular clinical and biological features of childhood GCT.
Moreover, the early observations have allowed tailoring ther-
apy more specifically to the pediatric setting and introducing
stratification of chemotherapy according to distinct risk
groups. 
This review summarizes the rapid development during recent
years, and describes what should be considered up-to-date
therapy of pediatric GCT. Lastly, this article outlines possible
future perspectives for treatment stratification that aim for
lower short- and long-term toxicity but maintain high overall
cure rates.
Epidemiology
In the pediatric age group, malignant GCT contribute 2.9% to
the central Tumor Registry of the German Society for Pedi-
atric Oncology and Hematology [1]. In Germany the inci-
dence of malignant GCT is 0.6/100,000 children up to 15 years
old. Since teratomas contribute additional 50%, the overall in-
cidence of GCT can be estimated as 0.9/100,000. The distribu-
tion of GCT with regard to tumor site and histology varies sig-
nificantly with age. In neonates mature and immature ter-
atomas predominate. In the first years of life the overall inci-
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Fig. 1. Computerized tomography of a 16-year-old girl with an ovarian
mixed malignant GCT with yolk sac tumor and immature teratoma com-
ponents (with kind permission of the Institute for Diagnostic Radiology,
Heinrich-Heine University, Düsseldorf).
Fig. 2. Local recurrence of a sacrococcygeal yolk sac tumor with prono-
unced gluteal swelling.
dence of GCT decreases, but among toddlers the relative pro-
portion of malignant tumors such as yolk sac tumors (YST)
increases. The incidence of gonadal tumors, mainly semino-
mas and dysgerminomas, increases with the onset of puberty.
In young men GCT represent the most common malignant
tumor at all. Figures 1–5 show typical examples of gonadal
and nongonadal GCT. 
Histologic Classification of Germ Cell Tumors
GCT are characterized by a profound heterogeneity of their
histologic differentiation. They are classified according to the
WHO classifications of testicular, ovarian or intracranial tu-
mors [2–4]. In our experience, these classifications constitute a
more precise morphologic description than the British classifi-
cation as they allow outlining all histologic components of
mixed malignant GCT. As intratumor heterogeneity may be
subtle, the initial diagnostic work-up should include the evalu-
ation by an experienced pediatric pathologist. According to
the guidelines of the German GCT protocols, a central histo-
logic evaluation is mandatory in order to achieve a standard-
ized and reliable histopathologic diagnosis and grading.
According to the holistic concept of Teilum [5, 6], GCT arise
from totipotent primordial germ cells which are capable of
embryonic and extraembryonic differentiation. YST and
choriocarcinoma (CHC) follow an extraembryonic differenti-
ation pattern and are characterized by significant secretion of
alpha1-fetoprotein (AFP) and human choriogonadotropin
(HCG or β-HCG), respectively (table 1) [7]. Embryonal carci-
noma (EC) represent tumors of immature totipotent cells.
Teratomas may mimic organ structures of all germ layers. The
histologic grade of immaturity of teratoma is defined by the
extent of immature (predominantly neuroepithelial) elements
[8]. Finally, germinomatous tumors (synonyms: seminoma
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(testis), dysgerminoma (ovary), germinoma (brain)) display
morphological features of undifferentiated germ epithelium.
In contrast to testicular GCT of adult patients, pediatric GCT
do not develop from carcinoma in situ [9].
In most patients, the response to the different therapeutic
modalities can be predicted from the histologic appearance
and the tumor marker profile (table 1). About 25% of all pe-
diatric GCT present as tumors with more than one histologic
type. In this situation therapy and prognosis depend on the
component with the highest malignancy.
Tumor Markers
The tumor markers AFP and/or β-HCG are helpful for clini-
cal diagnosis in tumors that present at a typical localization
(table 1) [7]. However, it has to be considered that serum AFP
may be excessively elevated in neonates and infants [10].
Therefore, in the first 2 years of life only AFP levels signifi-
cantly above the age-related normal value can be regarded as
diagnostic for a secreting GCT. In general, the tumor marker
profile is highly specific for the histologic differentiation of the
tumors (table 1). However, there may be a secretion of β-
chains of HCG in seminoma/germinoma (<50 IU/l) related to
syncytiotrophoblast-like giant cells. Some patients with imma-
ture teratoma may show a moderate elevation of the AFP
level (<100 µg/l), sometimes associated with histologically de-
tectable small foci of YST within the teratoma [11]. 
Biology
Molecular studies of the imprinting status of GCT revealed
that gonadal and nongonadal GCT share a common cellular
origin, the primordial germ cell although at different stages of
their development [12–14]. These data substantiate the hy-
pothesis that nongonadal GCT develop from germ cells that
have mislocated during their embryonic development. 
Pediatric GCT show a pattern of cytogenetic aberrations dif-
ferent from their adult counterparts. More than 80% of adult
malignant GCT display a distinct and specific chromosomal
aberration, the isochromosome 12p [15]. The remaining
16 Onkologie 2002;25:14–22 Göbel/Calaminus/Schneider/Schmidt/Haas
Fig. 3. Sagittal magnetic nuclear resonance tomography of an 18-month-
old-boy with a sacrococcygeal yolk sac tumor showing small extrapelvine
and large intrapelvine tumor components and pronounced tumor extensi-
on into the spinal canal (with kind permission of Dr. May, Dr. Rausch,
Diagnostic Radiologists, Düsseldorf).
Fig. 5. Sagittal magnetic nuclear resonance tomography of an 12-year-
old girl with an intracranial germinoma showing two tumor foci at the pi-
neal and suprasellar region (with kind permission of the Institute for Dia-
gnostic Radiology, Inner City Medical Center, Ludwig-Maximilians Uni-
versity, Munich).
Fig. 4. Computerized tomography of a 4-month-old girl with a vaginal
yolk sac tumor (with kind permission of the Institute for Diagnostic Ra-
diology, Heinrich-Heine University, Düsseldorf).
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isochromosome 12p-negative tumors frequently show amplifi-
cation of 12p (homogeneously staining regions or tandem re-
peats). These aberrations have been observed in both testicu-
lar and ovarian tumors and in mediastinal GCT. 
In children younger than 10 years an isochromosome 12p has
been found only in a small minority of malignant GCT [16,
17]. On the other hand, aberrations at both the short and the
long arm of chromosome 1, at the long arm of chromosome 6
and of the sex chromosomes have been found frequently [16].
Lastly, virtually all prepubertal teratomas are normal on con-
ventional cytogenetic analysis or on comparative genomic hy-
bridization [17–19].
Therapy
The Pre-Platinum Era
Until 1980, the prognosis of children with malignant GCT was
poor, and outcome was determined by the parameters age,
site, histology and stage. Only low-stage testicular YST in chil-
dren younger than 2 years and ovarian dysgerminoma had a
more favorable prognosis after radical resection [20–23]. 
The introduction of adjuvant chemotherapy with vincristin,
actinomycin D, and cyclophosphamide (VAC) in the 1960s
constituted a first and important step towards cure as for the
first time lasting complete remissions were achieved in a sig-
nificant proportion of patients [24–26]. However, the cure
rates in nonseminonatous GCT were still unsatisfactory as a
result of relapses during the first 2 years of follow-up.
Cisplatinum Chemotherapy 
The modern era of GCT chemotherapy began in the mid
1970s with the identification of the efficacy of cisplatinum in
testicular GCT. In 1977, Einhorn and Donohue [27] reported
a complete response rate of 85% in patients with metastatic
testicular GCT with a combination of cisplatinum, vinblastin,
and bleomycin (PVB) after tumor resection. Most important-
ly, the overall good response was also translated into durable
remissions. Nevertheless, relapses or refractory cancers – al-
though rare – established the need for second-line therapies,
and etoposide soon emerged as an active drug with a single-
agent efficacy superior to vinblastin [28]. In addition, the effi-
cacy of ifosfamide in cisplatinum-refractory GCT has been
documented. The combination of cisplatinum with etoposide
and ifosfamide for recurrent testicular GCT results in a 30%
durable remission rate and can now be considered standard
relapse treatment [29]. 
In relapsing and refractory GCT, the therapeutic value of
high-dose chemotherapy with autologous stem cell transplan-
tation has been investigated. These analyses have shown only
limited efficacy in prognostically unfavorable tumors such as
cisplatinum-resistant, mediastinal GCT with high β-HCG or
multiple relapses [30]. Nevertheless, in some patients intro-
duction of high-dose chemotherapy into first-line treatment of
high-risk tumors may be beneficial [31]. Lastly, ‘modern’ drugs
such as paclitaxel and gemcitabine are currently under investi-
gation.
Development of Cooperative Protocols for Pediatric GCT
Encouraged by the data discussed above, prospective pedi-
atric protocols for gonadal and nongonadal GCT were initiat-
ed. The first published trial was conducted by the US Chil-
dren’s Cancer Group (CCG) and included 54 children with
malignant nonseminomatous GCT. Patients underwent initial
resection followed by VAC + PVB chemotherapy over a 2-
year period [32]. 15 of 20 evaluable patients with ovarian non-
seminonatous GCT achieved complete remission. The prog-
nosis of children with nongonadal GCT was worse (complete
remission in 10/18 patients) but still encouraging compared to
all other previous studies. 
The consecutive CCG protocol included 93 children and con-
firmed the previous observation that gonadal GCT were more
favorable than nongondadal GCT (4-year event-free survival
(EFS) rates 63% vs. 42%) [33]. This difference was mainly at-
tributed to a higher rate of complete resections in gonadal tu-
mors.
Onkologie 2002;25:14–22Germ Cell Tumors in Children 17
Table 1. Biological characteristics of the histologic germ cell tumor subentities
Histological grading Tumor markers  Sensitivity to     
 
AFP ß-HCG  chemotherapy radiotherapy  
Seminoma/germinoma malignant – (+)  +++ ≥24 Gy 
EC malignant – –  +++ ≥45 Gy 
YST malignant +++ –  +++ ≥45 Gy 
CHC malignant – +++  +++ ≥45 Gy 
Teratoma, mature/immature benign/potentially malignant –/(+) –  ? ?
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In the consecutive US Intergroup protocol, the therapeutic
impact of cisplatinum dose intensification at 200 mg/m2/cycle
was evaluated. The interim analysis and the analysis of sacro-
coccygeal GCT reveal that cisplatinum escalation may in-
crease the therapeutic efficacy, however at an apparently high-
er renal and auditory toxicity [34, 35]. 
The analysis of the UKCCSG (United Kingdom Children’s
Cancer Study Group) study on malignant germ cell tumors
registered between 1979 and 1987 [36] included several
chemotherapy regimens: Low-dose VAC treatment was seen
to be ineffective (EFS rate 8%). The PVB combination (days
2, 9, 16) caused unacceptable pulmonary toxicity due to
bleomycin, whereas the combination of bleomycin (day 1
only), etoposide and cisplatinum (BEP) showed superior re-
sults with no proven pulmonary complication (EFS rate 84%).
Further analysis and comparison of different regimens of the
UKCCG GC I and GC II protocols also demonstrated the
high efficacy of platinum-based regimens such as BEP and
JEB (carboplatinum (600 mg/m2/cycle), etoposide, bleomycin)
that resulted in a 5-year EFS rate of 57% and 87% in nongo-
nadal GCT, respectively [37]. The recent analysis of the
UKCCG GC II study underscores the high efficacy of the JEB
regimen that resulted in a 5-year EFS rate of 88% [38].
The French study group first reported 35 children with ovarian
and nongonadal advanced-stage GCT treated with a VAC +
PB regimen (2-year survival rate 63%) [39]. In the consecutive
TGM 90 protocol, cisplatinum was replaced by carboplatinum
(400 mg/m2/cycle) [40, 41]. This regimen produced less favor-
able results than the British JEB regimen that used higher sin-
gle and cumulative doses of carboplatinum. In the current
French protocol, alternating combinations of cisplatinum with
etoposide or ifosfamide are administered, resulting in superior
response compared to the previous carboplatinum-based
strategy.
In both the French TGM 90 and the British GC II studies, the
analysis of prognostic factors revealed the impact of high AFP
serum levels at diagnosis, a finding that could not be con-
firmed by other studies that used a cisplatinum-based regimen
[42, 43] as well as the ongoing French protocol.
From 1982 on, the German protocols for testicular (MAHO)
and nontesticular (MAKEI) GCT included cisplatinum- and
etoposide-based regimens integrated into a multimodal ap-
proach that included delayed resection after preoperative or
neoadjuvant chemotherapy for advanced tumors [42–47]. As a
consequence of the excellent EFS rates above 80% achieved
with the first protocols, cumulative chemotherapy was step-
wise reduced from 8 cycles to 6 and currently to 4–5 cycles.
This reduction of cumulative chemotherapy did not affect out-
come [42, 43]. 
In summary, the regimens PEI (cisplatinum, etoposide and
ifosfamide), BEP, CarboPEI (carboplatinum, etoposide and
ifosfamide), and JEB have a synergistic cytotoxic activity and
can be regarded as standard regimens with comparable effica-
cy that are applied in currently open pediatric GCT protocols. 
Side Effects of Chemotherapy
Pulmonary toxicity of bleomycin appears to be particularly
problematic in combination with impaired kidney function
[48] or under anesthesia [49]. As a consequence, regimens
such as PEI that excluded bleomycin were evaluated. The
highly efficient combination PEI is associated with higher
myelosuppression and bears the risk of tubular nephropathy
[50]. In our experience with this regimen, we observed clini-
cally apparent hearing impairment in approximately 20% of
patients. Although auditory and renal toxicity of the carbo-
platinum regimen are smaller, carboplatinum at effective
doses (600 mg/m2/cycle) bears a substantial myelotoxicity [38].
The risk of therapy-related secondary leukemia is dependent
on the applied therapeutic modalities with an estimated cu-
mulative risk of 1.0% (3/442 patients, Kaplan-Meier method
at 10-year follow-up) for children treated with surgery and
chemotherapy only and 4.2% (3/174 patients) for children
treated with combined radio- and chemotherapy [51]. Never-
theless, the risk-benefit analysis still favors the use of etopo-
side in first-line treatment because of its excellent cytostatic
effect in childhood GCT.
Therapeutic Strategies of the International SIOP CNS
GCT 96 Protocol and the Currently Open German 
Protocols for Extracranial Germ Cell Tumors
The general therapeutic strategy may vary between different
protocols. Some protocols stratify the cumulative chemothera-
py according to the response to treatment (e.g. one standard
chemotherapy regimen to a total of 2 cycles after complete re-
mission [37, 38]). In other protocols, therapy is stratified ac-
cording to initial diagnostic parameters. In the following sec-
tions, the SIOP CNS GCT 96 protocol and the German proto-
cols for extracranial GCT and their risk-adapted therapeutic
strategies are summarized.
SIOP CNS GCT 96 Protocol on Malignant Intracranial GCT
Therapy for malignant intracranial GCT is stratified according
to the histologic differentiation (i.e. germinoma vs. malignant
nongerminomatous GCT) and stage. The ongoing SIOP CNS
GCT protocol evaluates two therapeutic options in intracran-
ial germinoma with regard to both their therapeutic impact
and their specific acute and long-term toxicity. For malignant
nongerminomatous intracranial tumors, the effect of com-
bined treatment with PEI and risk-adapted radiotherapy is ex-
amined.
In germinoma (fig. 5), which account for 50% of all intracra-
nial GCT and do not secret significant amounts of β-HCG,
histologic sampling is mandatory. According to the current
SIOP CNS GCT 96 protocol, patients can be treated either
18 Onkologie 2002;25:14–22 Göbel/Calaminus/Schneider/Schmidt/Haas
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with craniospinal irradiation with 24 Gy and tumor boost of 16
Gy or with a multimodal treatment including two cycles of
chemotherapy (CarboPEI) followed by focal irradiation (40
Gy). With radiotherapy only, a 5-year EFS rate of 91% and 5-
year overall survival rate of 94% can be achieved [52]. With
the combined chemo- and radiotherapy approach, a 3-year re-
lapse-free survival rate of 96% and an overall 3-year survival
rate of 98% have been reported. However, it should be con-
sidered that in this study 2 of the 4 observed events occurred
after the evaluated 3-year observation period [53]. Lastly,
strategies that excluded radiotherapy have not resulted in suf-
ficient tumor control [54].
Malignant nongerminomatous intracranial GCT (YST, CHC,
EC) have an inferior prognosis compared to germinoma. In
these patients 4 cycles of PEI are applied, followed by delayed
resection and radiotherapy. Radiotherapy is stratified accord-
ing to initial staging. Nonmetastatic tumors receive focal irra-
diation (54 Gy), whereas patients with intracranial or spinal
metastases or tumor cells in the cerebrospinal fluid receive
craniospinal irradiation (30 Gy plus 24 Gy tumor boost). The
meta-analysis of several cooperative protocols suggests that a
long-term remission can be obtained in about two thirds of
patients [55]. Again, strategies that exclude radiotherapy yield
inferior results [54].
MAHO and MAKEI Protocols on Extracranial Malignant
GCT
Surgical Treatment
Both gonadal and extragonadal GCT are treated according to
a similar therapeutic concept: Only in small tumors with no
evidence of invasive growth beyond the organ of origin or of
metastases, primary resection is recommended. In patients
with bulky, invasive or metastatic tumors, a preoperative
chemotherapy followed by delayed resection is preferred to
avoid incomplete resection. The decline of the tumor markers
according to their serum half-lifes indicates for a favorable re-
sponse to chemotherapy [7, 10, 56]. 
Resection is considered complete if performed as en-bloc re-
section of the tumor including the adjacent organ of origin.
The resection margins must be histologically free of tumor
cells. In testicular tumors, a high inguinal orchidectomy is
mandatory, and tumor biopsy is obsolete. Ovarian tumors (fig.
1) must be resected including ovary and Fallopian tube. In
coccygeal tumors (fig. 2, 3) the complete en toto resection in-
cluding the whole coccyx is essential [42, 57]. Additional at-
tention should be paid to potential extension of the tumor into
the spinal canal, which can be recognized on nuclear magnetic
resonance tomography (fig. 3). In this situation, preoperative
chemotherapy is advisable. A recently published review sum-
marizes the standard surgical procedures in gonadal and ex-
tragonadal GCT in detail [58]. The rare vaginal YST of infan-
cy (fig. 4) constitute the only exception as these very
chemosensitive tumors may also be cured without – according
to oncologic standards – radical resection [59].
In patients with residues after initial tumor resection, second-
look surgery is essential. Second-look surgery may at least
partly overcome the otherwise unfavorable prognostic impact
of incomplete resection [42, 43]. In general, there is no role for
debulking surgery in pediatric GCT. Usually, surgery of
metastases is not indicated unless they show insufficient re-
sponse to chemotherapy [42, 46, 60]. 
Adjuvant Treatment
According to the MAHO 98 protocol for testicular GCT, pa-
tients with stage IA mature teratoma or YST are treated ex-
pectantly. All other patients receive 2–3 cycles PVB (≤ stage
IIB) or the more intensive BEP (stages IIC–IV). PEI is re-
served to salvage therapy in patients with relapsing or poorly
responding tumors.
In the current MAKEI 96 protocol, patients with completely
resected stage T1 tumors are treated according to a watch-
and-wait strategy which includes frequent (weekly) controls
of the relevant tumor markers. Completely resected stage T2
tumors receive 2–3 cycles of a two-agent regimen (PE). A
three-agent combination is applied after incomplete resection
(PEI) [61]. Ovarian dysgerminoma are treated according to
the same strategy. Irradiation is omitted to preserve fertility. 
Teratoma
Teratomas represent a distinct histologic entity that shows a
significant diversity of the clinical course in dependence of the
histologic grade of immaturity [8, 57]. Mature teratomas are
considered benign tumors, whereas immature teratomas may
show clinical features of malignancy. Surgical treatment
should follow the same principles as outlined above for malig-
nant GCT.
The risk of recurrence can be estimated from the following
parameters: primary site of the tumor, histologic grade of im-
maturity, and completeness of the tumor resection [57]. 
The role of adjuvant chemotherapy has not yet been estab-
lished. However, recent reports have shown that chemothera-
py may not be indicated after complete resection, even in the
presence of small foci of YST [57, 62]. Incompletely resected
tumors have a 10% risk of relapse in mature and a 20% risk in
immature teratomas [57]. Half of the recurrent tumors may
display YST or EC histology. Adjuvant chemotherapy did not
reduce the risk of recurrence. However, no malignant relapses
have been seen after previous chemotherapy.
Follow-Up
Complete clinical remission is defined as normalization of
tumor markers within the age-related normal range and the
absence of suspicious residual structures. If any of these crite-
ria are not fulfilled, a diagnostic re-evaluation and – if neces-
Onkologie 2002;25:14–22Germ Cell Tumors in Children 19
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sary – change or intensification of treatment is urgently indi-
cated. Most relapses occur within the first 2 years after diag-
nosis. However, in some patients late recurrences 5 years or
later after diagnosis have been observed. Initial follow-up ex-
aminations after completion of chemotherapy must be per-
formed in short intervals, including frequent (i.e. weekly) con-
trols of the tumor markers AFP and β-HCG early during fol-
low-up. In watch-and-wait patients, the decline of the AFP
values must be evaluated with regard to its serum half-life of
approximately 6–7 days. Especially in infants younger than 2
years, the interpretation of AFP may be difficult due to the
physiologically elevated serum levels. In this context, it has
been proven helpful to compare the AFP decline to the age-
related reference values in neonates and infants [10]. A re-
tarded decline or a secondary rise of the AFP levels strongly
indicates for incomplete tumor resection or a recurrence of
YST [7]. 
In addition, follow-up must include repeated imaging of the
primary site of tumor. In case of residual structures after
chemotherapy of extracranial GCT, resection is indicated
since mature teratoma may have remained and bear the risk
of tumor progression [63]. In our experience, positron emis-
sion tomography examinations have not been proven useful in
this situation as these cannot distinguish between mature ter-
atoma and residual necrosis or scars [64].
In intracranial tumors, repeated endocrinologic examina-
tions at diagnosis and during follow-up are mandatory since
especially tumors of the suprasellar region can be associated
with diabetes insipidus or panhypopituiarism. In children
treated with cisplatinum and/or ifosfamide, the renal func-
tion has to be monitored carefully for tubular nephropathy.
In children, a prolonged phosphaturia may lead to renal
rickets with consecutive growth retardation while adoles-
cents are at risk of renal osteomalacia [50]. These long-term
sequelae can be avoided by supplementation of phosphate.
Further attention should be drawn to the risk of therapy-re-
lated secondary leukemia that depends on treatment inten-
sity and modality.
Relapse Treatment
In patients with recurrent or refractory tumors who had previ-
ously been treated with a non-platinum or carboplatinum
therapy, cisplatinum-based regimens (preferably PEI) have
been applied successfully [40, 61]. Therefore, we prefer cis-
platinum-containing regimens in patients with relapsed tu-
mors if the organ toxicity related to the previous treatment al-
lows further cisplatinum therapy. On the other hand, patients
with severe cisplatinum-related toxicity may be treated with a
combination of carboplatinum and high-dose etoposide (at
400–600 mg/m2 on 3 days). In our experience, high-dose
chemotherapy with stem cell support, as it has been applied in
adult patients [61], resulted in long-term remissions only in
those patients in whom a clinical complete remission could be
achieved prior to high-dose chemotherapy [60]. Therefore, we
would tend to reserve high-dose chemotherapy to consolida-
tion treatment. 
In our experience, more than 90% of relapses occur at the pri-
mary site of the tumor. For example, in our series of 104 sacro-
coccygeal YST only 2 patients had distant recurrences, where-
as 17 patients had local and 3 patients combined local and dis-
tant relapses [60]. Therefore, relapse chemotherapy must be
accompanied by an intensive local therapy, preferably com-
plete resection of the recurrent tumor after tumor reduction
by preoperative chemotherapy. We could demonstrate that
patients with local recurrences and poor response to conven-
tional chemotherapy may benefit from locoregional hyper-
thermia combined with platinum-based chemotherapy. This
approach significantly enhanced local tumor control [60, 65,
66]. However, the analysis of recurrent sacrococcygeal GCT
underscored the need to implement hyperthermia early as in
late relapse situations hyperthermia showed no beneficial ef-
fect, probably as a result of cisplatinum resistance or delayed
chemotherapy due to myelotoxicity of the previous treatment
[60]. Lastly, high-dose local irradiation at doses above 45 Gy
has shown some beneficial effects after incomplete resection
of the tumor recurrence, whereas irradiation at lower doses
was ineffective [60].
As insufficient local tumor control at the primary site of
tumor represents the main problem in most patients, further
significant advances in relapsing GCT may probably be based
on further improvement of local therapy.
Future Perspectives
A multimodal approach that utilizes cisplatinum/etoposide
chemotherapy as well as tumor resection is highly effective for
the treatment of pediatric GCT. In the light of the high cure
rates achieved by current protocols, research must now focus
on new aims. First, treatment must be further intensified in
those patients with cisplatinum-refractory or poorly respond-
ing tumors. The US study group evaluates a further dose esca-
lation of cisplatinum under protection with amifostine as a 200
mg/m2/cycle cisplatinum dose yielded a small but significant
survival advantage compared to a 100 mg/m2/cycle dose. How-
ever, results regarding toxicity are still pending. Furthermore,
results of alternative high-dose chemotherapy studies in re-
current GCT have to be awaited. Locoregional hyperthermia
constitutes an attractive alternative as cisplatinum represents
a very good thermosensitizer and hyperthermia may therefore
overcome cisplatinum resistance [60, 65, 66]. In addition, lo-
coregional hyperthermia should hopefully result in less sys-
temic side effects than cisplatinum dose escalation.
On the other hand, patients should be identified that are only
at a low risk of relapse and in whom adjuvant chemotherapy
can either be withheld or significantly reduced, thus allowing
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to minimize the impact on short- and long-term quality of life
and treatment toxicity.
In this context, molecular genetic studies may also reveal
some important information that may be utilized for risk strat-
ification. For example, in mediastinal GCT, genetic analysis
distinguishes two distinct genetic profiles by age that may cor-
relate with a poor (adults) or favorable (infants) prognosis
[19].
In conclusion, in the future clinical and molecular biologic in-
formation may allow distinguishing low-risk from high-risk
patients accurately and thereby allow designing a multimodal
approach to the individual patient.
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